Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 3,544

Document Document Title
WO/2019/173327A1
Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II).  
WO/2019/164947A1
The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method o...  
WO/2019/164948A1
The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, ...  
WO/2018/119362A8
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2019/103658A3
Derivatives having the general formula (I) and being limited to structural variants. The claimed compounds are used in the field of medicine as analgesics, anorexigenic or orexigenic agents for regulating weight (loss or gain), antidepre...  
WO/2019/120212A1
Disclosed in the present invention is a new class of compounds that act as indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitors, and specifically disclosed thereby are a compound represented by formula (I) and a pharmaceutically acceptab...  
WO/2019/115429A1
The invention relates to compounds according to the general formula (I) or a pharmaceutically acceptable salt of an inorganic or organic acid, a hydrate, a stereoisomer or a solvate thereof, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 a...  
WO/2019/103658A2
The invention relates to novel compounds that are derivatives of 1,4-benzodiazapin-2-one, having the general formula (I) and being limited to structural variants (1-6), on the condition that: а) structures 1 (R1=Br, R4=F), 3 (R1=OCF3, R...  
WO/2019/099560A1
The present subject matter provides compositions, formulations and methods for preventing or reducing proliferation or migration of retinal cells or epithelial to mesenchymal transition in ocular cells or cells from other tissues.  
WO/2019/094903A1
The present invention relates to processes and intermediates useful in the preparation of biologically active molecules, especially in the synthesis of Respiratory Syncytial Virus (RSV) inhibitors. The present invention also relates to p...  
WO/2019/086902A1
The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein X;Y; R1; R2; R3; R4; R5; R6; R7 and R8 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk o...  
WO/2019/087149A1
The present invention provides in one aspect azabicycio and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, t...  
WO/2019/082910A1
Provided are: a V2 receptor antagonist which has high water solubility and which is particularly suitable for injections; and a medicine containing the V2 receptor antagonist or the like. The present invention is a compound represented b...  
WO/2019/081691A1
The present invention relates to new compounds of formula (I) that show great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), or dual activity towards the subunit α2δ of voltage-gated calcium c...  
WO/2019/067864A1
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound ...  
WO/2019/056950A1
The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Sp...  
WO/2019/034532A1
The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7- carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compou...  
WO/2019/006459A1
Disclosed are methods and compositions related to STK1 inhibitors, such as Inh2-B1 (methyl 5-oxo-3-(phenyl carbamoyl)-1-thioxo-4,5dihydro[1,3]thiazolo[3,4-a]quinazolin e-8-carboxylate). The STK1 inhibitors can act as an antibiotic resist...  
WO/2018/233727A1
Provided are an indole compound and an application thereof. The compound is capable of effectively inhibiting CBP/EP300 bromodomain receptors, and may be used as a drug for cancers, inflammatory diseases, autoimmune diseases, septicaemia...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/119362A3
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/140186A1
The disclosure provides a simple and efficient method for producing a compound of Formula I. The method includes treating an N-substitututed-4-nitro-phthalimide of Formula VII with sodium or potassium phenoxide to form an N-substituted-4...  
WO/2018/129046A1
Disclosed herein are methods for modifying ciliogenesis in one or more cells of a subject, the method comprising administering to the subject an effective amount of a composition comprising a Notch signaling inhibitor, wherein the modifi...  
WO/2018/119362A2
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/083051A1
The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairm...  
WO/2018/069732A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...  
WO/2018/067102A1
The invention relates to medical chemistry, in particular to the use of 7-bromo-5-(o-chlorophenyl)-3-propoxy-l,2-dihydro-3H-l,4-benz odiazepin-2-one as a drug which inhibits neuropathic pain without the formation of defects in the gastri...  
WO/2018/044838A1
Methods for treating HIV in a human using combinations of: bictegravir and a maturation inhibitor, as well as compositions containing such compounds.  
WO/2018/044852A1
Methods for treating HIV in a human using combinations of: bictegravir and one two different maturation inhibitors are disclosed, as well as compositions containing such compounds are provided.  
WO/2018/044853A1
Methods for treating HIV in a human using combinations of: dolutegravir and a maturation inhibitor, as well as compositions containing such compounds.  
WO/2018/033714A1
The invention relates to compounds of formula (I), and pharmaceutical uses thereof. Particular aspects of the invention relate to methods of synthesising the compounds and the use of those compounds in treating, ameliorating, or preventi...  
WO/2018/008569A1
Provided is an industrially advantageous method for producing a compound (1), specifically a compound (1) in an amorphous form. A method for producing a calcium salt of a 1, 5-benzodiazepine compound represented by formula (1), which is ...  
WO/2017/205536A3
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical composition...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/211733A1
Relating to processes for preparing suvorexant or its pharmaceutically acceptable salts through the formation of a cocrystal of (R)-benzyl 5-methyl-1,4-diazepane-1-carboxylate hydrochloridewith (R)-(+)-1,1,2-triphenyl-1,2-ethanediol ((R)...  
WO/2017/205536A2
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compou...  
WO/2017/175854A1
The present invention provides a novel crystal of a compound A, the novel crystal being usable as a pharmaceutical product. Provided is a IV-type crystal of calcium (R)-(-)-3-[3-(1-tert-butylcarbonylmethyl-2-oxo-5-cyclohexyl- 1,3,4,5-tet...  
WO/2017/044849A8
The present invention provides compounds and pharmaceutically compositions thereof. The compounds and compositions are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also p...  
WO/2017/133620A1
The present invention relates to a synthesis process of suvorexant, and a preparation method of novel compounds represented by formulas II, III, IV or V, or a salt or intermediate thereof for preparing the suvorexant. The preparation met...  
WO/2017/063959A1
What are described are bromodomain-protein-inhibiting, especially BET protein-inhibiting and preferably BRD4-inhibiting, N-sulphoximinophenyl-substituted benzodiazepine derivatives of the general formula (I) in which R1, R2, R3, R4, and ...  
WO/2017/058915A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein A, B R1, R2a, R2b...  
WO/2017/044849A1
The present invention provides compounds and pharmaceutically compositions thereof. The compounds and compositions are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also p...  
WO/2017/030859A1
The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using ...  
WO/2017/029567A1
A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous appl...  
WO/2017/015784A1
The present invention belongs to the field of pharmaceutical chemistry, and particularly relates to an orbit azine-fumarate, a hydrate, a crystal form and a preparation method therefor. Specifically, in the present invention, different c...  
WO/2017/005711A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting phosphorous- and sulfur-substituted benzodiazepine derivatives of the general formula (I), in which R1, R2, R3,...  
WO/2016/207790A1
The present application provides a one-pot catalytic process which involves the formation of 1,4-dibenzodiazepines from o-haloaldimines (either pre-formed or formed in situ) of formula (I) and o-haloanilines of formula (II) via a palladi...  
WO/2016/176138A1
Disclosed are novel bis(aminophenylphenol) ligands and transition metal compounds derived therefrom. Also disclosed are methods of making the ligands and transition metal compounds.  
WO/2016/151464A1
The present invention provides an improved process for the preparation of 8-chloro-1-phenyl- 1H-benzo[b][1,4]diazepine-2,4(3H,5H)-dione (hereafter referred to as the compound (IV)), which is useful as a key intermediate for the synthesis...  
WO/2016/146048A1
Provided is an industrial manufacturing method for a midazolam derivative, said method being characterised in that: compound A and compound B undergo a cyclisation reaction under the conditions of a catalyst. The provided production meth...  

Matches 1 - 50 out of 3,544